Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma

Journal of Pathology

Volumn 232, Issue 4, 2014, Pages 386-390

  Caffarel, Maria M ^a   Coleman, Nicholas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

5p gain; angiogenesis; cell migration; cervix; invasion; oncostatin M receptor; squamous cell carcinoma

Indexed keywords

ONCOSTATIN M; ONCOSTATIN M RECEPTOR;

CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CHROMOSOME 5P; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; OSMR GENE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CARCINOMA;

5P GAIN; ANGIOGENESIS; CELL MIGRATION; CERVIX; INVASION; ONCOSTATIN M RECEPTOR; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 5; DRUG DESIGN; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; ONCOSTATIN M RECEPTOR BETA SUBUNIT; PHENOTYPE; SIGNAL TRANSDUCTION; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84893862934     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4305     Document Type: Review

References (50)

1. Arbyn M, Simoens C, Goffin F, et al., Treatment of cervical cancer precursors: influence of age, completeness of excision and cone depth on therapeutic failure, and on adverse obstetric outcomes. BJOG 2011; 118: 1274-1275; author reply 1275-1276.
2. Stanley MA,. Genital human papillomavirus infections: current and prospective therapies. J Gen Virol 2012; 93: 681-691.
3. Pett M, Coleman N,. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212: 356-367. (Pubitemid 47099012)
4. zur Hausen H. Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix. Lancet 1994; 343: 955-957.
5. Ng G, Winder D, Muralidhar B, et al., Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J Pathol 2007; 212: 325-334. (Pubitemid 47010066)
6. Narayan G, Murty VV,. Integrative genomic approaches in cervical cancer: implications for molecular pathogenesis. Future Oncol 2010; 6: 1643-1652.
7. Lando M, Wilting SM, Snipstad K, et al., Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling. J Pathol 2013; 230: 59-69.
8. Mine KL, Shulzhenko N, Yambartsev A, et al., Gene network reconstruction reveals cell cycle and antiviral genes as major drivers of cervical cancer. Nature Commun 2013; 4: 1806.
9. Atkin NB,. Cytogenetics of carcinoma of the cervix uteri: a review. Cancer Genet Cytogenet 1997; 95: 33-39. (Pubitemid 27188445)
10. Kirchhoff M, Rose H, Petersen BL, et al., Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999; 24: 144-150. (Pubitemid 29025260)
11. Scotto L, Narayan G, Nandula SV, et al., Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer 2008; 7: 58.
12. Jin C, Jin Y, Wennerberg J, et al., Cytogenetic abnormalities in 106 oral squamous cell carcinomas. Cancer Genet Cytogenet 2006; 164: 44-53. (Pubitemid 41820355)
13. Garnis C, Lockwood WW, Vucic E, et al., High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer 2006; 118: 1556-1564.
14. Huang FY, Kwok YK, Lau ET, et al., Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet 2005; 157: 42-48. (Pubitemid 40164857)
15. Pett MR, Alazawi WO, Roberts I, et al., Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 2004; 64: 1359-1368. (Pubitemid 38235604)
16. Pett MR, Herdman MT, Palmer RD, et al., Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc Natl Acad Sci U S A 2006; 103: 3822-3827. (Pubitemid 43376639)
17. Muralidhar B, Goldstein LD, Ng G, et al., Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol 2007; 212: 368-377. (Pubitemid 47099013)
18. Winder DM, Chattopadhyay A, Muralidhar B, et al., Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness. J Pathol 2011; 225: 448-462.
19. Muralidhar B, Winder D, Murray M, et al., Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. J Pathol 2011; 224: 496-507.
20. Narayan G, Bourdon V, Chaganti S, et al., Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer 2007; 46: 373-384. (Pubitemid 46411328)
21. Heinrich PC, Behrmann I, Haan S, et al., Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374: 1-20. (Pubitemid 37046923)
22. Tanaka M, Miyajima A,. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003; 149: 39-52.
23. Tamura S, Morikawa Y, Tanaka M, et al., Developmental expression pattern of oncostatin M receptor beta in mice. Mech Dev 2002; 115: 127-131. (Pubitemid 34615676)
24. West NR, Murphy LC, Watson PH,. Oncostatin M suppresses oestrogen receptor-alpha expression and is associated with poor outcome in human breast cancer. Endocr Relat Cancer 2012; 19: 181-195.
25. West NR, Murray JI, Watson PH,. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer. Oncogene 2013; DOI: 10.1038/onc.2013.105.
26. Guo L, Chen C, Shi M, et al., Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene 2013; 32: 5272-5282.
27. Liang H, Block TM, Wang M, et al., Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark 2012; 11: 161-171.
28. Royuela M, Ricote M, Parsons MS, et al., Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004; 202: 41-49. (Pubitemid 38072844)
29. Kan CE, Cipriano R, Jackson MW,. c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M. Cancer Res 2011; 71: 6930-6939.
30. Godoy-Tundidor S, Cavarretta IT, Fuchs D, et al., Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 2005; 64: 209-216. (Pubitemid 40791771)
31. Miles SA, Martinez-Maza O, Rezai A, et al., Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 1992; 255: 1432-1434.
32. Zhang XG, Gu JJ, Lu ZY, et al., Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 179: 1337-1342.
33. Zarling JM, Shoyab M, Marquardt H, et al., Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proc Natl Acad Sci U S A 1986; 83: 9739-9743. (Pubitemid 17223432)
34. Friedrich M, Hoss N, Stogbauer F, et al., Complete inhibition of in vivo glioma growth by oncostatin M. J Neurochem 2001; 76: 1589-1592. (Pubitemid 32198263)
35. Gibbs P, Chen Q, Robinson WA,. Effects of oncostatin M and tamoxifen on human melanoma cells. Melanoma Res 1998; 8: 221-226. (Pubitemid 28313759)
36. Liu J, Spence MJ, Wallace PM, et al., Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene. Cell Growth Differ 1997; 8: 667-676. (Pubitemid 27276397)
37. Jorcyk CL, Holzer RG, Ryan RE,. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine 2006; 33: 323-336. (Pubitemid 43948887)
38. Lee MJ, Heo SC, Shin SH, et al., Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI. Int J Biochem Cell Biol 2013; 45: 1869-1877.
39. Bolin C, Tawara K, Sutherland C, et al., Oncostatin M promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer 2012; 3: 117-130.
40. Diveu C, Venereau E, Froger J, et al., Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor. J Biol Chem 2006; 281: 36673-36682. (Pubitemid 46042134)
41. Chen D, Chu CY, Chen CY, et al., Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas. J Pathol 2008; 215: 290-299. (Pubitemid 351956710)
42. Kausar T, Sharma R, Hasan MR, et al., Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma. Cell Oncol (Dordr) 2011; 34: 177-187.
43. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev Cancer 2009; 9: 798-809.
44. Wang Z, Griffin M,. TG2, a novel extracellular protein with multiple functions. Amino Acids 2012; 42: 939-949.
45. Kumar S, Mehta K,. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids 2013; 44: 81-88.
46. Caffarel MM, Chattopadhyay A, Araujo AM, et al., Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma. J Pathol 2013; 231: 168-179.
47. Scott AM, Wolchok JD, Old LJ,. Antibody therapy of cancer. Nature Rev Cancer 2012; 12: 278-287.
48. Choi SI, Brahn E,. Rheumatoid arthritis therapy: advances from bench to bedside. Autoimmunity 2010; 43: 478-492.
49. Sharma SV, Haber DA, Settleman J,. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nature Rev Cancer 2010; 10: 241-253.
50. Tentler JJ, Tan AC, Weekes CD, et al., Patient-derived tumour xenografts as models for oncology drug development. Nature Rev Clin Oncol 2012; 9: 338-350.